NRx Pharma up on DSMB recommendation to continue enrollment for depression drug

NRX Pharmaceuticals

27/03/2023 14:08

** Shares of drug developer NRx Pharmaceuticals Inc  NRXP.O 
rise 6.86% to $0.78 premarket
    ** Co says the independent Data Safety Monitoring Board
(DSMB) recommended continuation of patient enrollment in ongoing
trial of co's NRX-101 in patients with suicidal
treatment-resistant bipolar depression as planned 
    ** DSMB reviewed the safety and efficacy findings of the
first 50 enrolled participants in the clinical trial of NRX-101,
no safety or futility signals were reported 
    ** NRXP has upgraded the ongoing trial to a mid-to-late
stage trial, results from which may be used in a future
registrational filing, should the primary goal be met; expects
topline data from this trial in Q4 2023
    ** Co lost ~76% last year

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))